Filing summary
Important entity clarification: Despite the request metadata naming Jasper Therapeutics, Inc., this is Amplitude Healthcare Acquisition Corporation’s unaudited Form 10-Q for the quarter ended June 30, 2021. Jasper appears as the proposed merger target; the filing does not report Jasper’s standalone financial results.
Business context and reporting period
Amplitude was a healthcare-focused blank-check company with no operating business or revenue as of June 30, 2021. Its activities were seeking and preparing for a business combination. The filing covers the three and six months ended June 30, 2021, compared with the corresponding 2020 periods.
Financial performance and liquidity
| Metric | Q2 2021 / June 30, 2021 | Comparable period / prior balance |
|---|---|---|
| Operating revenue | None | None; no operations commenced |
| General and administrative expenses | $562,032 for Q2; $776,434 for six months | $327,561 for Q2 2020; $556,227 for six months 2020 |
| Net income (loss) | $(3,569,534) for Q2; $1,928,537 for six months | $(3,432,059) for Q2 2020; $(2,003,200) for six months 2020 |
| Cash used in operating activities | $(678,626) for six months | $(406,720) for six months 2020 |
| Cash outside Trust Account | $309,730 | $770,114 at December 31, 2020 |
| Trust Account investments | $100,126,108 | $100,339,379 at December 31, 2020 |
| Current liabilities | $328,928 | $269,451 at December 31, 2020 |
| Warrant liability | $10,430,000 | $13,130,000 at December 31, 2020 |
| Deferred underwriting fee payable | $3,500,000 | $3,500,000 at December 31, 2020 |
The Q2 loss principally reflected a $3.01 million non-cash increase in warrant liability fair value, alongside operating expenses; Trust Account interest was $2,498. The six-month profit reflected a $2.70 million non-cash gain from the change in warrant liability fair value and $4,971 of interest, offset by expenses. These warrant revaluations materially affected reported earnings. Margins are not meaningful because the company had no revenue. The filing reports no long-term debt.
Material changes versus prior comparable periods
- Q2 net loss widened by about $137,000 from Q2 2020, while general and administrative expense increased by about $234,000.
- The six-month result moved from a $2.00 million net loss in 2020 to $1.93 million net income in 2021, primarily because the warrant fair-value change shifted from a $1.76 million expense to a $2.70 million gain.
- Six-month operating cash use increased by about $272,000 year over year. Cash outside the Trust Account fell by about $460,000 from year-end.
Transaction, outlook, risks, and unusual items
- On May 5, 2021, Amplitude agreed to merge with Jasper at a stated Jasper equity value of $275 million. The filing expected the transaction to close in Q3 2021, subject to approvals and other customary conditions.
- PIPE investors committed to purchase 10 million shares for $100 million, contingent on closing. Jasper’s minimum cash condition was $130 million, combining eligible Trust Account proceeds after redemptions with PIPE proceeds. The transaction also required at least $5,000,001 in net tangible assets at closing.
- Amplitude’s business-combination deadline was November 22, 2021. Management said failure to complete a transaction by then would require liquidation and dissolution and concluded that this raised substantial doubt about the company’s ability to continue as a going concern if no combination occurred.
- Trust Account funds were intended primarily for a business combination; the company had only $309,730 of cash outside the Trust Account. Sponsor or insider loans were possible but not committed. If the combination failed, public warrants could expire worthless.
- The filing reports a material weakness in disclosure controls, attributable to the prior restatement of warrant accounting. Remediation steps had begun but the weakness was not fully remediated as of June 30, 2021.
- COVID-19 could adversely affect the company’s finances or target search, but the specific impact was not determinable. Management reported no material market or interest-rate exposure from its short-term Treasury investments. No legal proceedings were reported.
Most important facts for investors to verify
- Confirm the correct issuer: this filing is Amplitude Healthcare Acquisition Corporation’s, not Jasper Therapeutics’ standalone 10-Q.
- Check the status and final terms of the proposed merger, including shareholder approvals, closing conditions, PIPE funding, redemptions, and the minimum cash requirement.
- Review the warrant-liability valuation and its large non-cash effect on earnings, as well as the prior warrant-accounting restatement.
- Assess the remaining cash outside the Trust Account, the November 22, 2021 business-combination deadline, and the going-concern warning.
- Review whether management’s control-remediation actions subsequently resolved the disclosed material weakness.